These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 10483112)

  • 1. Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines.
    Liljeqvist S; Ståhl S
    J Biotechnol; 1999 Jul; 73(1):1-33. PubMed ID: 10483112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fish vaccine antigens produced or delivered by recombinant DNA technologies.
    Leong JC; Anderson E; Bootland LM; Chiou PW; Johnson M; Kim C; Mourich D; Trobridge G
    Dev Biol Stand; 1997; 90():267-77. PubMed ID: 9270855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New approaches to the development of virus vaccines for veterinary use.
    Yamanouchi K; Barrett T; Kai C
    Rev Sci Tech; 1998 Dec; 17(3):641-53. PubMed ID: 9850535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccinia virus: a suitable vehicle for recombinant vaccines?
    Kaplan C
    Arch Virol; 1989; 106(1-2):127-39. PubMed ID: 2669685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccinia virus: a tool for research and vaccine development.
    Moss B
    Science; 1991 Jun; 252(5013):1662-7. PubMed ID: 2047875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies of constructing recombinant vaccines.
    Sałamaszyńska-Guz A; Klimuszko D
    Pol J Vet Sci; 2009; 12(1):133-9. PubMed ID: 19459451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects for the eradication of infectious diseases.
    Stuart-Harris C
    Rev Infect Dis; 1984; 6(3):405-11. PubMed ID: 6377445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antiviral vaccines].
    Girard M
    Med Trop (Mars); 1999; 59(4 Pt 2):522-6. PubMed ID: 10901858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New technologies for vaccines.
    Dorner F; Eibl J; Barrett PN
    Wien Klin Wochenschr; 1999 Mar; 111(5):199-206. PubMed ID: 10226350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Interleukin 12 Adjuvanted Herpes Simplex Virus 2 DNA Vaccine Is More Protective Than a Glycoprotein D Subunit Vaccine in a High-Dose Murine Challenge Model.
    Bagley KC; Schwartz JA; Andersen H; Eldridge JH; Xu R; Ota-Setlik A; Geltz JJ; Halford WP; Fouts TR
    Viral Immunol; 2017 Apr; 30(3):178-195. PubMed ID: 28085634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B5-deficient vaccinia virus as a vaccine vector for the expression of a foreign antigen in vaccinia immune animals.
    Viner KM; Girgis N; Kwak H; Isaacs SN
    Virology; 2007 May; 361(2):356-63. PubMed ID: 17188733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New technologies for vaccine development].
    Leclerc C
    Med Sci (Paris); 2007 Apr; 23(4):386-90. PubMed ID: 17433228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical development of Modified Vaccinia virus Ankara vaccines.
    Gilbert SC
    Vaccine; 2013 Sep; 31(39):4241-6. PubMed ID: 23523410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically engineered vaccines: an overview.
    Dertzbaugh MT
    Plasmid; 1998; 39(2):100-13. PubMed ID: 9514708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approaches to new vaccines.
    Mahon BP; Moore A; Johnson PA; Mills KH
    Crit Rev Biotechnol; 1998; 18(4):257-82. PubMed ID: 9887505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-replicating alphavirus RNA vaccines.
    Ljungberg K; Liljeström P
    Expert Rev Vaccines; 2015 Feb; 14(2):177-94. PubMed ID: 25269775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poxviruses as vaccine vectors.
    Pastoret PP; Vanderplasschen A
    Comp Immunol Microbiol Infect Dis; 2003 Oct; 26(5-6):343-55. PubMed ID: 12818621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of homologous and heterologous prime-boost immunizations combining MVA-vectored and plant-derived VP2 as a strategy against IBDV.
    Richetta M; Gómez E; Lucero MS; Chimeno Zoth S; Gravisaco MJ; Calamante G; Berinstein A
    Vaccine; 2017 Jan; 35(1):142-148. PubMed ID: 27876199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.
    Wang W; Li R; Deng Y; Lu N; Chen H; Meng X; Wang W; Wang X; Yan K; Qi X; Zhang X; Xin W; Lu Z; Li X; Bian T; Gao Y; Tan W; Ruan L
    Clin Vaccine Immunol; 2015 Jun; 22(6):618-30. PubMed ID: 25834017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.